Falipamil, formerly known as AQ-A-39, is a calcium channel antagonist potentially for the treatment of ischaemic heart disorder and sinus. Falipamil (AQ-A 39) is also a verapamil analogue which exerts antitachycardic effects by a direct action on the sinus node. Falipamil decreases HR at exercise in normal subjects and may exert antianginal effects in patients with myocardial ischemia. Falipamil exhibits effects on the electrical activity of the heart, reflecting the predominant direct vagolytic effect of this drug. References: Boucher M, Chassaing C, Chapuy E. Cardiac electrophysiological effects of falipamil in the conscious dog: comparison with alinidine. Eur J Pharmacol. 1996 Jun 13;306(1-3):93-8. PubMed PMID: 8813620.

纯度：≥98%

CAS：77862-92-1